Cryptitis high mag Jan

US-based Amgen (AMGN), Massachusetts General Hospital (MGH) and the Broad Institute have collaborated to jointly discover and validate new therapeutic targets and develop new therapies for inflammatory bowel disease (IBD).

The collaboration brings together scientists with expertise in clinical medicine, IBD biology, human genetics and genomic technology, as well as drug discovery to work together to help create a new world of therapeutic options for IBD patients.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Massachusetts General Hospital chief of gastroenterology Ramnik Xavier said the collaboration will translate discoveries of IBD genes and biology into novel drugs for IBD patients.

"We are thrilled to be working together with our Amgen colleagues in this visionary collaboration," Xavier added.

The partnership will leverage the shared expertise of its participating scientists and partner institutions to discover and develop novel therapies for IBD.

"The partnership will leverage the shared expertise of its participating scientists and partner institutions to discover and develop novel therapies for IBD."

As part of the collaboration, patient DNA samples will be collected and analysed to identify and further validate genetic targets, biological assays to probe gene function, and subsequent drug discovery and development activities.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The MGH-Broad-Amgen collaboration will also see formation of a new joint steering committee to select and guide projects.

The company said that IBD is well-known to run in families, suggesting that genes play a vital role in the development and progression of disease.

Amgen executive vice-president of research and development Sean Harper said: "We believe this collaboration with Massachusetts General Hospital and the Broad Institute will help identify improved treatment options for these patients."

Image: Micrograph showing inflammation of the large bowel in a case of inflammatory bowel disease. Photo: courtesy of Nephron.